• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.38 +1.45 (+4.17%)
Delayed Quote Updated: 12:54 PM EDT, Oct 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,526,239
Open 38.15
Bid (Size) 36.37 (100)
Ask (Size) 36.38 (300)
Prev. Close 34.92
Today's Range 36.13 - 38.49
52wk Range 17.28 - 42.50
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results ↗
Today 11:04 EDT
Roivant Sciences (NASDAQ:ROIV) reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis... 
Via MarketBeat
Topics Government
News headline image
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Today 7:00 EDT
From Roivant Sciences
Via GlobeNewswire

Performance

52-Week Range 14.4% below 52-week high
36.38
17.2852W Low 42.5052W High
1 Week
33.001W Low 35.521W High

Roivant Sciences Ltd. - Common Shares (ROIV) traded between $17.28 and $42.50 over the past 52 weeks and last traded at $36.38, 14.4% below its 52-week high. Over the past week it ranged between $33.00 and $35.52.

Past 12 Months
+8.2%
-6.7%
+4.0%
+24.2%
+65.9%
+105.0%
1W +$2.76
1M -$2.62
3M +$1.41
6M +$7.09
YTD +$14.45
1Y +$18.64

ROIV was +105.0% over the past year, +24.2% over six months, +65.9% year to date, +8.2% in the last week.

12 Months vs Market
ROIV
+105.0%
DIA
+12.7%
SPY
+15.2%
QQQ
+18.9%
IWM
+11.6%

Over the past 12 months ROIV returned +105.0% versus DIA (Dow) +12.7%, SPY (S&P 500) +15.2%, QQQ (Nasdaq 100) +18.9% and IWM (Russell 2000) +11.6%.

Volume & Liquidity 1.35× 3-mo avg
Today 9,526,239 3-mo avg 7.1M
1W
4.8M
1M
5.7M
3M
7.1M
6M
6.5M
YTD
6.4M
1Y
6.7M

ROIV most recently traded 9,526,239 shares against a 3-month average daily volume of 7.1M.

More News

Read More
News headline image
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Today 7:00 EDT
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months ↗
September 28, 2026
Via MarketBeat
Topics Government
News headline image
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
September 23, 2026
From Roivant Sciences
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
September 08, 2026
Via Chartmill
News headline image
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
September 08, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
September 08, 2026
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
September 06, 2026
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
September 06, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately ↗
August 28, 2026
Via MarketBeat
Topics Government
News headline image
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
August 26, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Sciences Q1 Earnings Call Highlights ↗
August 07, 2026
Via MarketBeat
Topics Earnings Government
News headline image
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
August 06, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
August 06, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗
July 07, 2026
Via The Motley Fool
News headline image
Roivant (ROIV) Q4 2025 Earnings Transcript ↗
May 20, 2026
Via The Motley Fool
News headline image
Roivant Sciences Q4 Earnings Call Highlights ↗
May 20, 2026
Via MarketBeat
Topics Earnings Government
Stay updated with the stocks that are on the move in today's pre-market session. ↗
May 20, 2026
Via Chartmill
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026
From Roivant Sciences
Via GlobeNewswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
May 18, 2026
Via The Motley Fool

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 36.38
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 10/21/26 12:54 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 25.17B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 25B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap